2. Neurological Disease

Neurological Disease

Neurological Disease

Related Products

PDF 88.0 MB

A range of neurological disorders, including epilepsy and dystonia, may involve dysfunctional intracortical inhibition, and may respond to treatments that modify it. Parkinson’s is a neurodegenerative disease characterized by increased activity of GABA in basal ganglia and the loss of dopamine in nigrostriatum, associated with rigidity, resting tremor, gait with accelerating steps, and fixed inexpressive face. Neurological deficits, along with neuromuscular involvement, are characteristic of mitochondrial disease, and these symptoms can have a dramatic impact on patient quality of life. Neurological features may be manifold, ranging from neural deafness, ataxia, peripheral neuropathy, migraine, seizures, stroke‐like episodes and dementia and depend on the part of the nervous system affected.

Cat. No. Product Name CAS No. Purity Chemical Structure
  • HY-151413A
    MEN 10207 acetate 98%
    MEN 10207 (acetate) is a selective antagonist of the NK-2 tachykinin receptor. MEN 10207 (acetate) induces tachykinin-induced contractions in rat bladder and guinea pig airways in vivo. MEN 10207 (acetate) inhibits [β-Ala 8 ]-NKA (4-10)-induced enhancement of bladder motility in anesthetized rats and [β-Ala 8 ]-NKA (4-10)-induced enhancement of bronchoconstriction in anesthetized guinea pigs.
    MEN 10207 acetate
  • HY-151546S
    MRS4596-d4
    MRS4596-d4 is the deuterium labeled MRS4596 (HY-151546). MRS4596 is a potent and selective P2X4 receptor antagonist with an IC50 value of 1.38 μM for human P2X4 receptor. MRS4596 has neuroprotective and neuro-rehabilitative activities in ischemic stroke model. MRS4596 can be used in research of ischemic stroke.
    MRS4596-d4
  • HY-151547S
    MRS4719-d3
    MRS4719-d3 is the deuterium labeled MRS4719 (HY-151547). MRS4719 is a potent P2X4 receptor antagonist with an IC50 value of 0.503 μM for human P2X4 receptor. MRS4719 can reduce infarct volume and reduce brain atrophy, showing neuroprotective and neuro-rehabilitative activities in ischemic stroke model. MRS4719 also reduces ATP-induced [Ca2+]i influx in primary human monocyte-derived macrophages. MRS4719 can be used to research ischemic stroke.
    MRS4719-d3
  • HY-151611A
    UAMC-00050 free base 934622-26-1
    UAMC-00050 free base is a potent trypsin-like serine protease inhibitor. UAMC-00050 free base can be used in research of dry eye syndrome and ocular inflammation.
    UAMC-00050 free base
  • HY-152014S
    Stearoylcarnitine-d3-1 hydrochloride 2692624-00-1 98%
    Stearoylcarnitine-d3-1 (hydrochloride) is deuterium labeled Stearoylcarnitine. Stearoylcarnitine, a fatty ester lipid molecule, is a human endogenous metabolite. Stearoylcarnitine acts as a metabolomics biomarker for early-onset-preeclampsia and late-onset-preeclampsia.
    Stearoylcarnitine-d3-1 hydrochloride
  • HY-153093A
    (1R,2R)-Elpipodect 1424378-99-3
    (1R,2R)-Elpipodect ((1R,2R)-MK-8189) is the (1R,2R) enantiomer of Elpipodect (HY-153093). Elpipodect (MK-8189) is an orally active and selective PDE10A inhibitor with a Ki of 29 pM. Elpipodect can be used in research of schizophrenia.
    (1R,2R)-Elpipodect
  • HY-153162A
    (-)-IHCH7041 2813335-07-6 98%
    (-)-IHCH7041 (Compound (-)-(S)-I-10) is a selective and orally active dopamine D2 receptor agonist with a Ki of 22.44 nM. (-)-IHCH7041 can activate Gαi1 protein and β-arrestin2 signaling pathway with EC50 values of 1.38 and 2.75 nM. (-)-IHCH7041 can improve cognitive impairment and memory capacity. (-)-IHCH7041 can be used for the research of neurological disease, such as Alzheimer's disease.
    (-)-IHCH7041
  • HY-153561A
    Lp-PLA2-IN-16 1865780-73-9 98%
    Lp-PLA2-IN-16 (example 1) is a lipoprotein-associated phospholipase A2 (Lp-PLA 2) inhibitor, which can be used in the research of Alzheimer's disease, etc.
    Lp-PLA2-IN-16
  • HY-153830S
    LacCer (d18:1/16:0)-d3 2097249-92-6 98%
    LacCer (d18:1/16:0) (C16 Lactosylceramide (d18:1/16:0))-d3 is the deuterium labeled LacCer (d18:1/16:0) (HY-153830). LacCer (d18:1/16:0) is an endogenous bioactive sphingolipid that can form membrane microdomains with Lyn kinase and the αi subunits of inhibitory G protein-coupled receptors (GPCRs). LacCer (d18:1/16:0) are elevated in the plasma of insulin-resistant cattle. LacCer (d18:1/16:0) is also upregulated in a mouse model of Niemann-Pick type C1 disease (a neurodegenerative cholesterol-sphingolipid lysosomal storage disorder). LacCer (d18:1/16:0) can be used in research on metabolic diseases and neurodegenerative diseases.
    LacCer (d18:1/16:0)-d3
  • HY-15414S3
    Vortioxetine-d3 1629684-22-5 98%
    Vortioxetine-d3 (Lu AA 21004-d3) is a deuterium labeled Vortioxetine (HY-15414). Vortioxetine (Lu AA 21004) is an antagonist of 5-HT3A and 5-HT7 receptors (Ki: 3.7 nM, 19 nM) and an inhibitor of serotonin transporter (SERT) (Ki: 1.6 nM), as well as a 5-HT1A agonist and a partial agonist of 5-HT1B (Ki: 15 nM, 33 nM).
    Vortioxetine-d3
  • HY-155185A
    NMDA receptor antagonist 8 3033746-14-1 98%
    NMDA receptor antagonist 8 (Compound (R)-10a) is GluN2B subunit-selective NMDA Receptor antagonist, with an Ki of 265 nM and an IC50 of 62 nM. NMDA receptor antagonist 8 can be used for research of neurodegenerative diseases.
    NMDA receptor antagonist 8
  • HY-155330A
    PZ-1922 free base 1648745-65-6 98%
    PZ-1922 free base is a BBB-penetrable 5-HT6R/5-HT3R antagonist (Ki: 17 nM, 0.45 nM for 5-HT6R/5-HT3R respectively). PZ-1922 free base reversibly inhibits MAO-B (pIC50: 8.93). PZ-1922 free base reverses Scopolamine (SCOP) (HY-N0296) induced memory deficits in the novel object recognition (NOR) test in rats. PZ-1922 free base prevents Aβ-induced memory decline in the T-maze test.
    PZ-1922 free base
  • HY-156438A
    (S)-Ruvonoflast 99.65%
    (S)-Ruvonoflast ((S)-NT-0796) is the S-isomer of Ruvonoflast (HY-156438). Ruvonoflast (NT-0796) is an orally active, selective, centrally nervous system-transporting NLRP3 inflammasome inhibitor.
    (S)-Ruvonoflast
  • HY-156505A
    R-(+)-EU-1180-453 2488764-06-1 98%
    R-(+)-EU-1180-453 is a positive allosteric modulator targeting NMDA receptors containing GluN2C and GluN2D subunits, with a pEC50 value of 5.5 for both rat receptor subtypes, and it can cross the blood-brain barrier. R-(+)-EU-1180-453 increases the potency of glutamate, enhances receptor responses to maximally effective concentrations of agonists, and acts only on receptors bound to both co-agonists. R-(+)-EU-1180-453 is applicable to research related to Alzheimer's disease, Parkinson's disease, epilepsy, and neuropathic pain.
    R-(+)-EU-1180-453
  • HY-156532A
    5-HT2C agonist-3 free base 2104810-17-3 98%
    5-HT2C agonist-3 ((+)-19) free base is a selective 5-HT2C agonist (EC50: 24 nM, Ki: 78 nM). 5-HT2C agonist-3 free base has antipsychotic drug-like activity. 5-HT2C agonist-3 free base blocks Amphetamine-induced hyperactivity.
    5-HT2C agonist-3 free base
  • HY-156533A
    5-HT2 agonist-1 free base 2708279-77-8 98%
    5-HT2 agonist-1 (Compound 24) free base is a 5-HT2A & 5-HT2B & 5-HT2C agonist, with IC50s of 10 nM, 8.3, and 1.6 nM respectively. 5-HT2 agonist-1 free base can be used for research of depression, alcoholism, tobacco and cocaine addiction, inflammation, cluster headache, PTSD, seizure disorders and other CNS disorders.
    5-HT2 agonist-1 free base
  • HY-156596A
    Aneratrigine hydrochloride 2097163-75-0 98%
    Aneratrigine (hydrochloride) is a sodium channel protein type 9 subunit alpha blocker. Aneratrigine (hydrochloride) can be used for neuropathic pain diseases research.
    Aneratrigine hydrochloride
  • HY-156600A
    Bevemipretide trihydrochloride 2589640-11-7
    Bevemipretide trihydrochloride (SBT-272 trihydrochloride) is a blood-brain barrier-permeable mitochondrial function repair agent. Bevemipretide trihydrochloride stabilizes cardiolipin in the inner mitochondrial membrane, restores mitochondrial structure, respiratory function, motor capacity and upper motor neuron health. Bevemipretide trihydrochloride reduces astrogliosis and microgliosis in mice with amyotrophic lateral sclerosis. Bevemipretide trihydrochloride prevents stroke-induced mitochondrial dysfunction. Bevemipretide trihydrochloride is applicable to research related to amyotrophic lateral sclerosis, Parkinson's disease, dementia with Lewy bodies and Huntington's disease.
    Bevemipretide trihydrochloride
  • HY-156650A
    Votoplam hydrochloride 2407851-28-7
    Votoplam (PTC518) hydrochloride is an HTT gene regulator with an IC50 ≤ 0.1 μM. Votoplam hydrochloride can be used in the research of Huntington's disease.
    Votoplam hydrochloride
  • HY-157955A
    TAAR1 agonist 1 hydrochloride 98%
    TAAR1 agonist 1 hydrochloride (6e·HCl) is a novel G-protein-coupled receptor TAAR1 agonist. TAAR1 agonist 1 hydrochloride is used in the study of schizophrenia.
    TAAR1 agonist 1 hydrochloride
Cat. No. Product Name / Synonyms Application Reactivity